文献速递中医内科中药与中成药合理使用

中药制剂治疗颈动脉粥样硬化的疗效与安全性:系统评价与Meta分析

Efficacy and safety of selected Chinese herbal medicine preparations in treating carotid atherosclerosis: a systematic review and meta-analyses.
PubMed 文献 · Front Pharmacol · 2026-10-02

该系统评价与Meta分析纳入21项RCT共3078例患者,评估口服中药辅助常规治疗颈动脉粥样硬化的疗效与安全性。结果显示辅助中药可显著减小颈动脉斑块面积、IMT,改善血脂,且不显著增加不良事件风险。网络分析提示核心治法为化痰祛瘀,丹参、半夏为关键药物。

要点

  • 辅助中药可显著减小颈动脉斑块面积和IMT,改善血脂谱。
  • 中药不显著增加不良事件风险,未损害肝肾功能。
  • 核心治法为化痰祛瘀,丹参、半夏为关键药物。

核心结论

  • 作为常规治疗的辅助,中药可能进一步减小颈动脉IMT和斑块负荷、改善脂代谢,并显示良好安全性。
  • 但纳入研究的整体质量和异质性限制了证据强度,需高质量RCT确认。

研究设计与样本

  • 系统评价与Meta分析,检索5个数据库从建库至2025年12月。
  • 纳入评估口服中药治疗颈动脉粥样硬化的RCT,共21项RCT、3078例患者。
  • 使用Cochrane RoB 2工具评估研究质量,采用RevMan v5.3和R软件分析。
  • 通过网络分析揭示21项研究的中药用药规律。

主要发现

  • 与单纯常规治疗相比,辅助中药显著减小颈动脉斑块面积(MD=4.94,95%CI:3.13至6.76,p<0.01)。
  • 辅助中药显著降低IMT(MD=0.12,95%CI:0.07至0.17,p<0.05)。
  • 辅助中药显著降低TC(MD=0.32,95%CI:0.22至0.42,p<0.01)、TG(MD=0.24,95%CI:0.11至0.37,p<0.01)和LDL-C(MD=0.37,95%CI:0.21至0.53,p<0.01)。
  • 辅助中药显著升高HDL-C(MD=-0.20,95%CI:-0.29至-0.10,p<0.01)。
  • 中药不显著增加不良事件风险(RR=0.84,95%CI:0.64至1.10,p=0.20),未损害肝肾功能。

关键数值与推荐

  • 纳入标准为评估口服中药治疗颈动脉粥样硬化的RCT。
  • 网络分析识别核心作用为化痰祛瘀,丹参和半夏为关键植物药,发挥抗瘀和调脂作用。

临床怎么用

  • 在常规治疗基础上,可考虑辅助使用以化痰祛瘀为法的中药(如丹参、半夏)以改善颈动脉斑块和血脂。
  • 使用中药辅助时需关注安全性,尽管研究未显示显著增加不良事件。

局限性

  • 纳入研究的整体质量和异质性限制了证据强度。
  • 需要设计良好的高质量RCT确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although conventional therapies for Carotid atherosclerosis (CAS) remain the standard treatment, their effectiveness is often limited and accompanied by adverse effects. Chinese herbal medicine (CHM) is a promising adjunctive therapy for CAS; however, robust clinical evidence supporting its efficacy and safety remains limited. OBJECTIVE: This systematic review and meta-analysis evaluates the efficacy and safety of CHM for CAS treatment and characterizes its medication patterns. METHODS: Five databases were searched from inception to December 2025. Randomized controlled trials (RCTs) evaluating oral CHM for CAS were included. Study quality was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Data were extracted and analyzed using RevMan v5.3 and R software. Sources of heterogeneity were investigated through meta-regression and subgroup analyses. Network analysis reveals herbal medication patterns across 21 studies. RESULTS: Twenty-one RCTs involving 3,078 patients were included. Compared with conventional therapy alone, adjunctive CHM significantly reduced carotid plaque area (MD = 4.94, 95% CI: 3.13 to 6.76, p < 0.01), intima-media thickness (IMT) (MD = 0.12, 95% CI: 0.07 to 0.17, p < 0.05), total cholesterol (TC) (MD = 0.32, 95% CI: 0.22 to 0.42, p < 0.01), triglycerides (TG) (MD = 0.24, 95% CI: 0.11 to 0.37, p < 0.01), and low-density lipoprotein cholesterol (LDL-C) (MD = 0.37, 95% CI: 0.21 to 0.53, p < 0.01), while greatly increasing high-density lipoprotein cholesterol (HDL-C) (MD = -0.20, 95% CI: -0.29 to -0.10, p < 0.01). CHM did not significantly increase the risk of adverse events (RR = 0.84, 95% CI: 0.64 to 1.10, p = 0.20) or impair liver/kidney function. Network analysis identified core actions as clearing phlegm and removing blood stasis, with Danshen (Salvia miltiorrhiza Bge.) and Banxia [Pinellia ternata (Thunb.) Breit.] as pivotal botanical drugs exerting anti-stasis and lipid-regulating effects. CONCLUSION: As an adjunct to conventional therapy, CHM may further reduce carotid IMT and plaque burden, improve lipid metabolism, and demonstrate a favorable safety profile. However, the overall quality and heterogeneity of the included studies limit the strength of the evidence, highlighting the need for well-designed, high-quality RCTs to confirm these findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261285381, identifier CRD420261285381.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Feng M, Zhang H, et al. Efficacy and safety of selected Chinese herbal medicine preparations in treating carotid atherosclerosis: a systematic review and meta-analyses. Front Pharmacol. 2026. PMID: 42890206. doi:10.3389/fphar.2026.1903096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。